{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:30:56Z","timestamp":1792589456234,"version":"4.5.0"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"This work was supported and funded by the Deanship of Scientific Research at Imam Mohammad Ibn Saud Islamic University","award":["MSIU-DDRSP2601)"],"award-info":[{"award-number":["MSIU-DDRSP2601)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-36406-4","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T09:37:17Z","timestamp":1768901837000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["From in-silico QSAR modeling to in-vitro MTT assay: experimental validation of novel uPAR leads for triple-negative breast cancer (TNBC) and skin cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Harshal","family":"Badukle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul D.","family":"Jawarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umang","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somdutta","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah Yahya Abdullah","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Samad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami A.","family":"Al-Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aamal A.","family":"Al-Mutairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdi E.A.","family":"Zaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"36406_CR1","doi-asserted-by":"publisher","unstructured":"Siegel, R. L., Giaquinto, A. N., Jemal, A. & Cancer statistics, 2024. CA: A Cancer Journal for Clinicians 74, 12\u201349, https:\/\/doi.org\/10.3322\/caac.21820 (2024).","DOI":"10.3322\/caac.21820"},{"key":"36406_CR2","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.apsb.2015.07.005","volume":"5","author":"X Guan","year":"2015","unstructured":"Guan, X. Cancer metastases: challenges and opportunities. Acta Pharm. Sinica B. 5, 402\u2013418. https:\/\/doi.org\/10.1016\/j.apsb.2015.07.005 (2015).","journal-title":"Acta Pharm. Sinica B"},{"key":"36406_CR3","doi-asserted-by":"publisher","first-page":"5574","DOI":"10.1002\/cam4.2474","volume":"8","author":"H Dillek\u00e5s","year":"2019","unstructured":"Dillek\u00e5s, H., Rogers, M. S. & Straume, O. Are 90% of deaths from cancer caused by metastases? Cancer Med. 8, 5574\u20135576. https:\/\/doi.org\/10.1002\/cam4.2474 (2019).","journal-title":"Cancer Med."},{"key":"36406_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1615\/CritRevOncog.v18.i1-2.40","volume":"18","author":"TN Seyfried","year":"2013","unstructured":"Seyfried, T. N. & Huysentruyt, L. C. On the origin of cancer metastasis. Crit. Reviews\u2122 Oncog. 18, 43\u201373. https:\/\/doi.org\/10.1615\/CritRevOncog.v18.i1-2.40 (2013).","journal-title":"Crit. Reviews\u2122 Oncog."},{"key":"36406_CR5","doi-asserted-by":"publisher","unstructured":"Hudock, N. L. et al. Future trends in incidence and long-term survival of metastatic cancer in the united States. Commun. Med. 3 https:\/\/doi.org\/10.1038\/s43856-023-00304-x (2023).","DOI":"10.1038\/s43856-023-00304-x"},{"key":"36406_CR6","doi-asserted-by":"publisher","unstructured":"Vogt, A. et al. Multiple primary tumours: challenges and approaches, a review. ESMO Open. 2 https:\/\/doi.org\/10.1136\/esmoopen-2017-000172 (2017).","DOI":"10.1136\/esmoopen-2017-000172"},{"key":"36406_CR7","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1586\/14737140.2014.911091","volume":"14","author":"D Li","year":"2014","unstructured":"Li, D., Kang, J. & Madoff, D. C. Locally ablative therapies for primary and metastatic liver cancer. Expert Rev. Anticancer Ther. 14, 931\u2013945. https:\/\/doi.org\/10.1586\/14737140.2014.911091 (2014).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"36406_CR8","doi-asserted-by":"publisher","unstructured":"Sgalambro, F. et al. Interventional radiology in the management of metastases and bone tumors. J. Clin. Med. 11 https:\/\/doi.org\/10.3390\/jcm11123265 (2022).","DOI":"10.3390\/jcm11123265"},{"key":"36406_CR9","doi-asserted-by":"publisher","unstructured":"Kolling, S. et al. Metastatic cancer of unknown primary or primary metastatic cancer? Front. Oncol. 9 https:\/\/doi.org\/10.3389\/fonc.2019.01546 (2020).","DOI":"10.3389\/fonc.2019.01546"},{"key":"36406_CR10","doi-asserted-by":"publisher","unstructured":"Mauro, C. D. et al. Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors. Sci. Rep. 7 https:\/\/doi.org\/10.1038\/s41598-017-10062-1 (2017).","DOI":"10.1038\/s41598-017-10062-1"},{"key":"36406_CR11","doi-asserted-by":"publisher","unstructured":"Santibanez, J. F. Urokinase type plasminogen activator and the molecular mechanisms of its regulation in cancer. Protein Pept. Lett. 24 https:\/\/doi.org\/10.2174\/0929866524666170818161132 (2018).","DOI":"10.2174\/0929866524666170818161132"},{"key":"36406_CR12","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.4161\/cc.28921","volume":"13","author":"Y Bao","year":"2014","unstructured":"Bao, Y. et al. Urokinase-type plasminogen activator receptor signaling is critical in nasopharyngeal carcinoma cell growth and metastasis. Cell. Cycle. 13, 1958\u20131969. https:\/\/doi.org\/10.4161\/cc.28921 (2014).","journal-title":"Cell. Cycle"},{"key":"36406_CR13","doi-asserted-by":"publisher","first-page":"30897","DOI":"10.1074\/jbc.M109.011213","volume":"284","author":"X Cheng","year":"2009","unstructured":"Cheng, X., Shen, Z., Yin, L., Lu, S. H. & Cui, Y. ECRG2 regulates cell Migration\/Invasion through Urokinase-type plasmin activator receptor (uPAR)\/\u03b21 integrin pathway. J. Biol. Chem. 284, 30897\u201330906. https:\/\/doi.org\/10.1074\/jbc.M109.011213 (2009).","journal-title":"J. Biol. Chem."},{"key":"36406_CR14","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.biopha.2012.10.003","volume":"67","author":"L Tang","year":"2013","unstructured":"Tang, L. & Han, X. The urokinase plasminogen activator system in breast cancer invasion and metastasis. Biomed. Pharmacother. 67, 179\u2013182. https:\/\/doi.org\/10.1016\/j.biopha.2012.10.003 (2013).","journal-title":"Biomed. Pharmacother."},{"key":"36406_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s000180050497","volume":"57","author":"PA Andreasen","year":"2000","unstructured":"Andreasen, P. A., Egelund, R. & Petersen, H. H. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell. Mol. Life Sci. (CMLS). 57, 25\u201340. https:\/\/doi.org\/10.1007\/s000180050497 (2000).","journal-title":"Cell. Mol. Life Sci. (CMLS)"},{"key":"36406_CR16","doi-asserted-by":"publisher","unstructured":"Bharadwaj, A. G., Holloway, R. W., Miller, V. A. & Waisman, D. M. Plasmin and plasminogen system in the tumor microenvironment: implications for cancer Diagnosis, Prognosis, and therapy. Cancers 13 https:\/\/doi.org\/10.3390\/cancers13081838 (2021).","DOI":"10.3390\/cancers13081838"},{"key":"36406_CR17","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s000180300039","volume":"60","author":"JM Rakic","year":"2003","unstructured":"Rakic, J. M. et al. Role of plasminogen activator-plasmin system in tumor angiogenesis. Cell. Mol. Life Sci. (CMLS). 60, 463\u2013473. https:\/\/doi.org\/10.1007\/s000180300039 (2003).","journal-title":"Cell. Mol. Life Sci. (CMLS)"},{"key":"36406_CR18","doi-asserted-by":"publisher","unstructured":"Minaei, E. et al. Cancer progression gene expression profiling identifies the urokinase plasminogen activator receptor as a biomarker of metastasis in cutaneous squamous cell carcinoma. Front. Oncol. 12 https:\/\/doi.org\/10.3389\/fonc.2022.835929 (2022).","DOI":"10.3389\/fonc.2022.835929"},{"key":"36406_CR19","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.12.4.911","author":"SA Rabbani","year":"1998","unstructured":"Rabbani, S. A. & Xing, R. H. Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies. Int. J. Oncol. https:\/\/doi.org\/10.3892\/ijo.12.4.911 (1998).","journal-title":"Int. J. Oncol."},{"key":"36406_CR20","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1002\/1098-1128(200103)21:2<146","volume":"21","author":"Y Wang","year":"2001","unstructured":"Wang, Y. The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis. Med. Res. Rev. 21, 146\u2013170. https:\/\/doi.org\/10.1002\/1098-1128(200103)21:2%3C146 (2001). ::Aid-med1004>3.0.Co;2-b","journal-title":"Med. Res. Rev."},{"key":"36406_CR21","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s10585-006-9004-3","volume":"22","author":"CR Dass","year":"2006","unstructured":"Dass, C. R. et al. Downregulation of uPAR confirms link in growth and metastasis of osteosarcoma. Clin. Exp. Metastasis. 22, 643\u2013652. https:\/\/doi.org\/10.1007\/s10585-006-9004-3 (2006).","journal-title":"Clin. Exp. Metastasis"},{"key":"36406_CR22","doi-asserted-by":"publisher","first-page":"7026","DOI":"10.7150\/jca.62281","volume":"12","author":"T Lv","year":"2021","unstructured":"Lv, T. et al. uPAR: an essential factor for tumor development. J. Cancer. 12, 7026\u20137040. https:\/\/doi.org\/10.7150\/jca.62281 (2021).","journal-title":"J. Cancer"},{"key":"36406_CR23","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.18632\/oncotarget.1754","volume":"5","author":"F Margheri","year":"2014","unstructured":"Margheri, F. et al. The receptor for urokinase-plasminogen activator (uPAR) controls plasticity of cancer cell movement in mesenchymal and amoeboid migration style. Oncotarget 5, 1538\u20131553. https:\/\/doi.org\/10.18632\/oncotarget.1754 (2014).","journal-title":"Oncotarget"},{"key":"36406_CR24","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.1097\/01.blo0000093845.72468.bd","volume":"415","author":"PFM Choong","year":"2003","unstructured":"Choong, P. F. M. & Nadesapillai, A. P. W. Urokinase plasminogen activator system. Clin. Orthop. Relat. Res. 415, S46\u2013S58. https:\/\/doi.org\/10.1097\/01.blo0000093845.72468.bd (2003).","journal-title":"Clin. Orthop. Relat. Res."},{"key":"36406_CR25","doi-asserted-by":"publisher","unstructured":"Schuliga, M. & Kleinjan, A. The Inflammatory Actions of Coagulant and Fibrinolytic Proteases in Disease. Mediators of Inflammation 2015, https:\/\/doi.org\/10.1155\/2015\/437695 (2015).","DOI":"10.1155\/2015\/437695"},{"key":"36406_CR26","doi-asserted-by":"publisher","unstructured":"Li Santi, A., Napolitano, F., Montuori, N. & Ragno, P. The urokinase receptor: A multifunctional receptor in cancer cell Biology. Therapeutic implications. Int. J. Mol. Sci. 22 https:\/\/doi.org\/10.3390\/ijms22084111 (2021).","DOI":"10.3390\/ijms22084111"},{"key":"36406_CR27","doi-asserted-by":"publisher","unstructured":"Hamada, M. et al. Urokinase-Type plasminogen activator receptor (uPAR) in inflammation and disease: A unique inflammatory pathway activator. Biomedicines 12 https:\/\/doi.org\/10.3390\/biomedicines12061167 (2024).","DOI":"10.3390\/biomedicines12061167"},{"key":"36406_CR28","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s12307-015-0172-z","volume":"8","author":"RL Eefsen","year":"2015","unstructured":"Eefsen, R. L. et al. Inflammation and uPAR-Expression in colorectal liver metastases in relation to growth pattern and Neo-adjuvant therapy. Cancer Microenvironment. 8, 93\u2013100. https:\/\/doi.org\/10.1007\/s12307-015-0172-z (2015).","journal-title":"Cancer Microenvironment"},{"key":"36406_CR29","doi-asserted-by":"publisher","unstructured":"Mahmood, N., Mihalcioiu, C. & Rabbani, S. A. Multifaceted role of the Urokinase-Type plasminogen activator (uPA) and its receptor (uPAR): Diagnostic, Prognostic, and therapeutic applications. Front. Oncol. 8 https:\/\/doi.org\/10.3389\/fonc.2018.00024 (2018).","DOI":"10.3389\/fonc.2018.00024"},{"key":"36406_CR30","doi-asserted-by":"publisher","unstructured":"Ahn, S. B. et al. Proteomics reveals Cell-Surface urokinase plasminogen activator receptor expression impacts most hallmarks of cancer. Proteomics 19 https:\/\/doi.org\/10.1002\/pmic.201900026 (2019).","DOI":"10.1002\/pmic.201900026"},{"key":"36406_CR31","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1055\/s-0038-1675399","volume":"118","author":"J Maduni\u0107","year":"2018","unstructured":"Maduni\u0107, J. The urokinase plasminogen activator system in human cancers: an overview of its prognostic and predictive role. Thromb. Haemost. 118, 2020\u20132036. https:\/\/doi.org\/10.1055\/s-0038-1675399 (2018).","journal-title":"Thromb. Haemost."},{"key":"36406_CR32","doi-asserted-by":"publisher","unstructured":"El Hasasna, H. et al. Rhus coriaria suppresses angiogenesis, metastasis and tumor growth of breast cancer through Inhibition of STAT3, NF\u03baB and nitric oxide pathways. Sci. Rep. 6 https:\/\/doi.org\/10.1038\/srep21144 (2016).","DOI":"10.1038\/srep21144"},{"key":"36406_CR33","doi-asserted-by":"publisher","unstructured":"Moirangthem, A. et al. Simultaneous knockdown of uPA and MMP9 can reduce breast cancer progression by increasing cell-cell adhesion and modulating EMT genes. Sci. Rep. 6 https:\/\/doi.org\/10.1038\/srep21903 (2016).","DOI":"10.1038\/srep21903"},{"key":"36406_CR34","doi-asserted-by":"publisher","first-page":"7733","DOI":"10.2147\/ott.S187221","volume":"11","author":"D Meng","year":"2018","unstructured":"Meng, D. et al. MicroRNA-645 targets urokinase plasminogen activator and decreases the invasive growth of MDA-MB-231 triple-negative breast cancer cells. OncoTargets Therapy. 11, 7733\u20137743. https:\/\/doi.org\/10.2147\/ott.S187221 (2018).","journal-title":"OncoTargets Therapy"},{"key":"36406_CR35","doi-asserted-by":"publisher","unstructured":"Huber, M. C. et al. uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R. BMC Cancer. 16 https:\/\/doi.org\/10.1186\/s12885-016-2663-9 (2016).","DOI":"10.1186\/s12885-016-2663-9"},{"key":"36406_CR36","doi-asserted-by":"publisher","unstructured":"Haque, M., Shyanti, R. K. & Mishra, M. K. Targeted therapy approaches for epithelial-mesenchymal transition in triple negative breast cancer. Front. Oncol. 14 https:\/\/doi.org\/10.3389\/fonc.2024.1431418 (2024).","DOI":"10.3389\/fonc.2024.1431418"},{"key":"36406_CR37","doi-asserted-by":"publisher","unstructured":"Zolota, V. et al. Epigenetic alterations in Triple-Negative breast Cancer\u2014The critical role of extracellular matrix. Cancers 13 https:\/\/doi.org\/10.3390\/cancers13040713 (2021).","DOI":"10.3390\/cancers13040713"},{"key":"36406_CR38","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s13402-021-00620-1","volume":"44","author":"WY Hung","year":"2021","unstructured":"Hung, W. Y. et al. Blocking MMP-12-modulated epithelial-mesenchymal transition by repurposing penfluridol restrains lung adenocarcinoma metastasis via uPA\/uPAR\/TGF-\u03b2\/Akt pathway. Cell. Oncol. 44, 1087\u20131103. https:\/\/doi.org\/10.1007\/s13402-021-00620-1 (2021).","journal-title":"Cell. Oncol."},{"key":"36406_CR39","doi-asserted-by":"publisher","unstructured":"Fedele, M., Cerchia, L. & Chiappetta, G. The Epithelial-to-Mesenchymal transition in breast cancer: focus on Basal-Like carcinomas. Cancers 9 https:\/\/doi.org\/10.3390\/cancers9100134 (2017).","DOI":"10.3390\/cancers9100134"},{"key":"36406_CR40","doi-asserted-by":"publisher","unstructured":"Dubot, P. et al. Potential role of Sphingolipidoses-Associated lysosphingolipids in cancer. Cancers 14 https:\/\/doi.org\/10.3390\/cancers14194858 (2022).","DOI":"10.3390\/cancers14194858"},{"key":"36406_CR41","doi-asserted-by":"publisher","unstructured":"Ioannou, P., Katsoulieris, E. & Afratis, N. A. Matrix dynamics and Microbiome crosstalk: matrix metalloproteinases as key players in disease and therapy. Int. J. Mol. Sci. 26 https:\/\/doi.org\/10.3390\/ijms26083621 (2025).","DOI":"10.3390\/ijms26083621"},{"key":"36406_CR42","doi-asserted-by":"publisher","unstructured":"Zhang, L. et al. Targets of tumor microenvironment for potential drug development. MedComm \u2013 Oncol. 3 https:\/\/doi.org\/10.1002\/mog2.68 (2024).","DOI":"10.1002\/mog2.68"},{"key":"36406_CR43","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423\u20131437. https:\/\/doi.org\/10.1038\/nm.3394 (2013).","journal-title":"Nat. Med."},{"key":"36406_CR44","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1016\/j.ajpath.2014.08.003","volume":"184","author":"J Hu","year":"2014","unstructured":"Hu, J. et al. uPAR induces expression of transforming growth factor \u03b2 and Interleukin-4 in cancer cells to promote Tumor-Permissive conditioning of macrophages. Am. J. Pathol. 184, 3384\u20133393. https:\/\/doi.org\/10.1016\/j.ajpath.2014.08.003 (2014).","journal-title":"Am. J. Pathol."},{"key":"36406_CR45","doi-asserted-by":"publisher","unstructured":"Zhao, H. et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal. Transduct. Target. Therapy. 6 https:\/\/doi.org\/10.1038\/s41392-021-00658-5 (2021).","DOI":"10.1038\/s41392-021-00658-5"},{"key":"36406_CR46","doi-asserted-by":"publisher","unstructured":"Zhai, B. T. et al. Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer. J. Translational Med. 20 https:\/\/doi.org\/10.1186\/s12967-022-03329-3 (2022).","DOI":"10.1186\/s12967-022-03329-3"},{"key":"36406_CR47","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1007\/s00018-008-7573-9","volume":"65","author":"CH Tang","year":"2008","unstructured":"Tang, C. H. & Wei, Y. The urokinase receptor and integrins in cancer progression. Cell. Mol. Life Sci. 65, 1916\u20131932. https:\/\/doi.org\/10.1007\/s00018-008-7573-9 (2008).","journal-title":"Cell. Mol. Life Sci."},{"key":"36406_CR48","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.2174\/138945011797635902","volume":"12","author":"K Lund","year":"2011","unstructured":"Lund, K., Illemann, I., Thurison, M., Christensen, T. J., Hoyer-Hansen, G. & I. & uPAR as Anti-Cancer target: evaluation of biomarker Potential, histological Localization, and Antibody-Based therapy. Curr. Drug Targets. 12, 1744\u20131760. https:\/\/doi.org\/10.2174\/138945011797635902 (2011).","journal-title":"Curr. Drug Targets"},{"key":"36406_CR49","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/nrm2821","volume":"11","author":"HW Smith","year":"2010","unstructured":"Smith, H. W. & Marshall, C. J. Regulation of cell signalling by uPAR. Nat. Rev. Mol. Cell Biol. 11, 23\u201336. https:\/\/doi.org\/10.1038\/nrm2821 (2010).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"36406_CR50","doi-asserted-by":"publisher","unstructured":"Centini, G. et al. Fertility sparing in endometrial cancer. Where Are We Now? Cancers. 17 https:\/\/doi.org\/10.3390\/cancers17010112 (2025).","DOI":"10.3390\/cancers17010112"},{"key":"36406_CR51","doi-asserted-by":"publisher","unstructured":"Moholkar, D. N., Kandimalla, R., Gupta, R. C. & Aqil, F. Advances in lipid-based carriers for cancer therapeutics: Liposomes, exosomes and hybrid exosomes. Cancer Lett. 565 https:\/\/doi.org\/10.1016\/j.canlet.2023.216220 (2023).","DOI":"10.1016\/j.canlet.2023.216220"},{"key":"36406_CR52","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jdermsci.2023.11.004","volume":"113","author":"M Takagi","year":"2024","unstructured":"Takagi, M. et al. A modified Sobel filter-based automated numerical algorithm enables immediate trichoscopic assessment of hair diameter diversity in male and female pattern hair loss. J. Dermatol. Sci. 113, 38\u201340. https:\/\/doi.org\/10.1016\/j.jdermsci.2023.11.004 (2024).","journal-title":"J. Dermatol. Sci."},{"key":"36406_CR53","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s43153-023-00332-z","volume":"41","author":"A Madani","year":"2023","unstructured":"Madani, A., Benkortbi, O. & Laidi, M. In Silico prediction of the Inhibition of new molecules on SARS-CoV-2 3CL protease by using QSAR: PSOSVR approach. Braz. J. Chem. Eng. 41, 427\u2013442. https:\/\/doi.org\/10.1007\/s43153-023-00332-z (2023).","journal-title":"Braz. J. Chem. Eng."},{"key":"36406_CR54","doi-asserted-by":"publisher","first-page":"7262","DOI":"10.1021\/acs.jmedchem.2c00254","volume":"65","author":"Z Cai","year":"2022","unstructured":"Cai, Z., Zafferani, M., Akande, O. M. & Hargrove, A. E. Quantitative structure\u2013Activity relationship (QSAR) study predicts Small-Molecule binding to RNA structure. J. Med. Chem. 65, 7262\u20137277. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c00254 (2022).","journal-title":"J. Med. Chem."},{"key":"36406_CR55","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/cad.0000000000001492","volume":"35","author":"M Er-rajy","year":"2024","unstructured":"Er-rajy, M., El fadili, M., Faris, A., Zarougui, S. & Elhallaoui, M. Design of potential anti-cancer agents as COX-2 inhibitors, using 3D-QSAR modeling, molecular docking, oral bioavailability proprieties, and molecular dynamics simulation. Anti-Cancer Drugs. 35, 117\u2013128. https:\/\/doi.org\/10.1097\/cad.0000000000001492 (2024).","journal-title":"Anti-Cancer Drugs"},{"key":"36406_CR56","doi-asserted-by":"publisher","unstructured":"Jawarkar, R. D. et al. QSAR modelling to predict structural features of certain sulfonamide as Urokinase-type plasminogen activator inhibitors. Chem. Phys. Impact. 8 https:\/\/doi.org\/10.1016\/j.chphi.2024.100544 (2024).","DOI":"10.1016\/j.chphi.2024.100544"},{"key":"36406_CR57","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1021\/jm050149r","volume":"49","author":"BA Bhongade","year":"2005","unstructured":"Bhongade, B. A. & Gadad, A. K. Insight into the structural requirements of Urokinase-Type plasminogen activator inhibitors based on 3D QSAR CoMFA\/CoMSIA models. J. Med. Chem. 49, 475\u2013489. https:\/\/doi.org\/10.1021\/jm050149r (2005).","journal-title":"J. Med. Chem."},{"key":"36406_CR58","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1002\/cmdc.201300340","volume":"8","author":"T Mani","year":"2013","unstructured":"Mani, T. et al. Probing binding and cellular activity of pyrrolidinone and piperidinone small molecules targeting the urokinase receptor. ChemMedChem 8, 1963\u20131977. https:\/\/doi.org\/10.1002\/cmdc.201300340 (2013).","journal-title":"ChemMedChem"},{"key":"36406_CR59","doi-asserted-by":"publisher","unstructured":"Chang, Y. C., Wu, C. Z., Cheng, C. W., Chen, J. S. & Chang, L. C. Redrawing urokinase receptor (uPAR) signaling with cancer driver genes for exploring possible Anti-Cancer targets and drugs. Pharmaceuticals 16 https:\/\/doi.org\/10.3390\/ph16101435 (2023).","DOI":"10.3390\/ph16101435"},{"key":"36406_CR60","doi-asserted-by":"publisher","first-page":"4386","DOI":"10.1039\/c7ra12912b","volume":"8","author":"J Liu","year":"2018","unstructured":"Liu, J. et al. Current research on anti-breast cancer synthetic compounds. RSC Adv. 8, 4386\u20134416. https:\/\/doi.org\/10.1039\/c7ra12912b (2018).","journal-title":"RSC Adv."},{"key":"36406_CR61","doi-asserted-by":"publisher","unstructured":"Er-rajy, M. et al. Design of novel anti-cancer agents targeting COX-2 inhibitors based on computational studies. Arab. J. Chem. 16 https:\/\/doi.org\/10.1016\/j.arabjc.2023.105193 (2023).","DOI":"10.1016\/j.arabjc.2023.105193"},{"key":"36406_CR62","doi-asserted-by":"publisher","unstructured":"Khan, S., Sarfraz, A., Prakash, O. & Khan, F. Machine learning-based QSAR modeling, molecular docking, dynamics simulation studies for cytotoxicity prediction in MDA-MB231 triple-negative breast cancer cell line. J. Mol. Struct. 1315 https:\/\/doi.org\/10.1016\/j.molstruc.2024.138807 (2024).","DOI":"10.1016\/j.molstruc.2024.138807"},{"key":"36406_CR63","doi-asserted-by":"publisher","unstructured":"Er-rajy, M. et al. Design and evaluation of novel Triazole derivatives as potential anti-gout inhibitors: a comprehensive molecular modeling study. Front. Chem. 13 https:\/\/doi.org\/10.3389\/fchem.2025.1518777 (2025).","DOI":"10.3389\/fchem.2025.1518777"},{"key":"36406_CR64","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1080\/08927022.2024.2331237","volume":"50","author":"Y Zhan","year":"2024","unstructured":"Zhan, Y. & Zhang, S. Design of novel PLK4 inhibitors as TRIM37-amplified breast cancer drugs using 3D-QSAR, molecular docking, and molecular dynamics simulation methods. Mol. Simul. 50, 571\u2013587. https:\/\/doi.org\/10.1080\/08927022.2024.2331237 (2024).","journal-title":"Mol. Simul."},{"key":"36406_CR65","doi-asserted-by":"publisher","unstructured":"Zheng, Y. et al. The role of artificial intelligence in the development of anticancer therapeutics from natural polyphenols: current advances and future prospects. Pharmacol. Res. 208 https:\/\/doi.org\/10.1016\/j.phrs.2024.107381 (2024).","DOI":"10.1016\/j.phrs.2024.107381"},{"key":"36406_CR66","doi-asserted-by":"publisher","first-page":"8870","DOI":"10.1021\/acs.jmedchem.0c02218","volume":"64","author":"S Zhu","year":"2021","unstructured":"Zhu, S. et al. Inhibiting eukaryotic elongation factor 2 kinase: an update on Pharmacological Small-Molecule compounds in cancer. J. Med. Chem. 64, 8870\u20138883. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c02218 (2021).","journal-title":"J. Med. Chem."},{"key":"36406_CR67","doi-asserted-by":"publisher","unstructured":"Chunarkar-Patil, P. et al. Anticancer drug discovery based on natural products: from computational approaches to clinical studies. Biomedicines 12 https:\/\/doi.org\/10.3390\/biomedicines12010201 (2024).","DOI":"10.3390\/biomedicines12010201"},{"key":"36406_CR68","doi-asserted-by":"publisher","unstructured":"Er-rajy, M. et al. Exploring donor-acceptor characteristics and adsorption behavior of a naphthamide-based inhibitor for protective surfaces through a molecular modeling approach. J. Indian Chem. Soc. 102 https:\/\/doi.org\/10.1016\/j.jics.2025.101640 (2025).","DOI":"10.1016\/j.jics.2025.101640"},{"key":"36406_CR69","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1080\/10629360902949567","volume":"20","author":"JC Dearden","year":"2009","unstructured":"Dearden, J. C., Cronin, M. T. D. & Kaiser, K. L. E. How not to develop a quantitative structure\u2013activity or structure\u2013property relationship (QSAR\/QSPR). SAR QSAR Environ. Res. 20, 241\u2013266. https:\/\/doi.org\/10.1080\/10629360902949567 (2009).","journal-title":"SAR QSAR Environ. Res."},{"key":"36406_CR70","doi-asserted-by":"publisher","first-page":"4977","DOI":"10.1021\/jm4004285","volume":"57","author":"A Cherkasov","year":"2014","unstructured":"Cherkasov, A. et al. QSAR modeling: where have you been? where are you going to? J. Med. Chem. 57, 4977\u20135010. https:\/\/doi.org\/10.1021\/jm4004285 (2014).","journal-title":"J. Med. Chem."},{"key":"36406_CR71","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1021\/mp100423u","volume":"8","author":"J Huang","year":"2011","unstructured":"Huang, J., Fan, X., Why, Q. S. A. R. & Fails An empirical evaluation using conventional computational approach. Mol. Pharm. 8, 600\u2013608. https:\/\/doi.org\/10.1021\/mp100423u (2011).","journal-title":"Mol. Pharm."},{"key":"36406_CR72","doi-asserted-by":"crossref","unstructured":"Gramatica, P. et al. QSAR modeling is not push a button and find a correlation: a case study of toxicity of (benzo-) Triazoles on algae. Molecular Pharmaceutics31, 817\u2013835 (2012).","DOI":"10.1002\/minf.201200075"},{"key":"36406_CR73","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s11030-009-9212-2","volume":"14","author":"J Li","year":"2009","unstructured":"Li, J. & Gramatica, P. The importance of molecular structures, endpoints\u2019 values, and predictivity parameters in QSAR research: QSAR analysis of a series of Estrogen receptor binders. Mol. Diversity. 14, 687\u2013696. https:\/\/doi.org\/10.1007\/s11030-009-9212-2 (2009).","journal-title":"Mol. Diversity"},{"key":"36406_CR74","doi-asserted-by":"crossref","unstructured":"Masand, V. H., Rastija, V. J. C. & Systems, I. L. PyDescriptor: A new PyMOL plugin for calculating thousands of easily understandable molecular descriptors. Molecular Informatic169, 12\u201318 (2017).","DOI":"10.1016\/j.chemolab.2017.08.003"},{"key":"36406_CR75","unstructured":"Gramatica, P., Chirico, N., Papa, E., Cassani, S. & Kovarich, S. (Wiley Online Library, 2013)."},{"key":"36406_CR76","doi-asserted-by":"publisher","unstructured":"Zaki, M. et al. (ed, E.) Identification of Anti-SARS-CoV-2 compounds from food using QSAR-Based virtual Screening, molecular Docking, and molecular dynamics simulation analysis. Pharmaceuticals 14 https:\/\/doi.org\/10.3390\/ph14040357 (2021).","DOI":"10.3390\/ph14040357"},{"key":"36406_CR77","doi-asserted-by":"publisher","unstructured":"Masand, V. H. et al. Balanced QSAR analysis to identify the structural requirements of ABBV-075 (Mivebresib) analogues as bromodomain and extraterminal domain (BET) family bromodomain inhibitor. J. Mol. Struct. 1229 https:\/\/doi.org\/10.1016\/j.molstruc.2020.129597 (2021).","DOI":"10.1016\/j.molstruc.2020.129597"},{"key":"36406_CR78","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1002\/jcc.23361","volume":"34","author":"P Gramatica","year":"2013","unstructured":"Gramatica, P., Chirico, N., Papa, E., Cassani, S. & Kovarich, S. QSARINS: A new software for the development, analysis, and validation of QSAR MLR models. J. Comput. Chem. 34, 2121\u20132132. https:\/\/doi.org\/10.1002\/jcc.23361 (2013).","journal-title":"J. Comput. Chem."},{"key":"36406_CR79","doi-asserted-by":"crossref","unstructured":"Tropsha, A. in Molecular, Clinical and Environmental Toxicology Experientia Supplementum Ch. Chapter 13, 381\u2013411 (2012).","DOI":"10.1007\/978-3-7643-8340-4_13"},{"key":"36406_CR80","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s10822-011-9440-2","volume":"25","author":"I Sushko","year":"2011","unstructured":"Sushko, I. et al. Online chemical modeling environment (OCHEM): web platform for data storage, model development and publishing of chemical information. J. Comput. Aided Mol. Des. 25, 533\u2013554. https:\/\/doi.org\/10.1007\/s10822-011-9440-2 (2011).","journal-title":"J. Comput. Aided Mol. Des."},{"key":"36406_CR81","doi-asserted-by":"publisher","unstructured":"O\u2019Boyle, N. M. et al. Open babel: an open chemical toolbox. J. Cheminform. 3 https:\/\/doi.org\/10.1186\/1758-2946-3-33 (2011).","DOI":"10.1186\/1758-2946-3-33"},{"key":"36406_CR82","doi-asserted-by":"publisher","first-page":"7206","DOI":"10.1039\/c7cp08010g","volume":"20","author":"Q Shao","year":"2018","unstructured":"Shao, Q. & Zhu, W. Assessing AMBER force fields for protein folding in an implicit solvent. Phys. Chem. Chem. Phys. 20, 7206\u20137216. https:\/\/doi.org\/10.1039\/c7cp08010g (2018).","journal-title":"Phys. Chem. Chem. Phys."},{"key":"36406_CR83","doi-asserted-by":"publisher","first-page":"15917","DOI":"10.1039\/c7ra00370f","volume":"7","author":"U Yadava","year":"2017","unstructured":"Yadava, U., Yadav, V. K. & Yadav, R. K. Novel anti-tubulin agents from plant and marine origins: insight from a molecular modeling and dynamics study. RSC Adv. 7, 15917\u201315925. https:\/\/doi.org\/10.1039\/c7ra00370f (2017).","journal-title":"RSC Adv."},{"key":"36406_CR84","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1080\/07391102.2020.1747545","volume":"39","author":"S Bharadwaj","year":"2020","unstructured":"Bharadwaj, S., Rao, A. K., Dwivedi, V. D., Mishra, S. K. & Yadava, U. Structure-based screening and validation of bioactive compounds as Zika virus methyltransferase (MTase) inhibitors through first-principle density functional theory, classical molecular simulation and QM\/MM affinity Estimation. J. Biomol. Struct. Dynamics. 39, 2338\u20132351. https:\/\/doi.org\/10.1080\/07391102.2020.1747545 (2020).","journal-title":"J. Biomol. Struct. Dynamics"},{"key":"36406_CR85","doi-asserted-by":"publisher","unstructured":"Bharadwaj, S. et al. Drug repurposing for ligand-induced rearrangement of Sirt2 active site-based inhibitors via molecular modeling and quantum mechanics calculations. Sci. Rep. 11 https:\/\/doi.org\/10.1038\/s41598-021-89627-0 (2021).","DOI":"10.1038\/s41598-021-89627-0"},{"key":"36406_CR86","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1021\/ct900587b","volume":"6","author":"D Shivakumar","year":"2010","unstructured":"Shivakumar, D. et al. Prediction of absolute solvation free energies using molecular dynamics free energy perturbation and the OPLS force field. J. Chem. Theory Comput. 6, 1509\u20131519. https:\/\/doi.org\/10.1021\/ct900587b (2010).","journal-title":"J. Chem. Theory Comput."},{"key":"36406_CR87","doi-asserted-by":"crossref","unstructured":"Chirico, N. & Gramatica, P. J. J. o. c. i. & modeling. Real external predictivity of QSAR models: how to evaluate it? Comparison of different validation criteria and proposal of using the concordance correlation coefficient. J Chem Inf Model51, 2320\u20132335 (2011).","DOI":"10.1021\/ci200211n"},{"key":"36406_CR88","doi-asserted-by":"crossref","unstructured":"Gaulton, A. et al. The chembl database in 2017. Nucleic Acids Res45, D945\u2013D954 (2017).","DOI":"10.1093\/nar\/gkw1074"},{"key":"36406_CR89","doi-asserted-by":"crossref","unstructured":"Tosco, P., Balle, T. & Shiri, F. J. J. o. c.-a. m. d. Open3DALIGN: an open-source software aimed at unsupervised ligand alignment. J Comput Aided Mol Des25, 777\u2013783 (2011).","DOI":"10.1007\/s10822-011-9462-9"},{"key":"36406_CR90","unstructured":"Bowers, K. J. et al. in Proceedings of the 2006 ACM\/IEEE conference on Supercomputing-SC\u201906. (ACM Press)."},{"key":"36406_CR91","doi-asserted-by":"crossref","unstructured":"Jorgensen, W. L., Maxwell, D. S. & Tirado-Rives, J. J. J. o. t. a. c. s. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. Journal of the American Chemical Society118, 11225\u201311236 (1996).","DOI":"10.1021\/ja9621760"},{"key":"36406_CR92","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/0092-8674(86)90782-8","volume":"45","author":"MP Stoppelli","year":"1986","unstructured":"Stoppelli, M. P. et al. Autocrine saturation of pro-urokinase receptors on human A431 cells. Cell 45, 675\u2013684. https:\/\/doi.org\/10.1016\/0092-8674(86)90782-8 (1986).","journal-title":"Cell"},{"key":"36406_CR93","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1046\/j.1523-1747.1999.00631.x","volume":"113","author":"C Marschall","year":"1999","unstructured":"Marschall, C. et al. UVB increases Urokinase-Type plasminogen activator receptor (uPAR) Expression1. J. Invest. Dermatology. 113, 69\u201376. https:\/\/doi.org\/10.1046\/j.1523-1747.1999.00631.x (1999).","journal-title":"J. Invest. Dermatology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36406-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36406-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36406-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T22:02:21Z","timestamp":1770847341000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36406-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":93,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["36406"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-36406-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"5 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The MMT assay was carried out at Department of Pharmaceutical Chemistry, Ramanbhai Patel College of Pharmacy, CHARUSAT Campus, Changa, Gujarat 388421. The source of cell line used in the study were procured from the National Center for Cell Science, Pune.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Cell line studies & source of cell line"}}],"article-number":"5786"}}